Sollis Therapeutics Stock

sollistx.comHealthcareFounded: 2017Funding to Date: $49.89MM

Sollis Therapeutics is a clinical-stage pharmaceutical company developing novel interventional non-steroid, non-opioid analgesics.

Register for Details

For more details on financing and valuation for Sollis Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Sollis Therapeutics.

Register Today

Team

Management Team

Gregory Fiore MD
Co-Founder, Chief Executive Officer, President and Board Member
Bryan Jones JD
Chief Operating Officer & Co-Founder

Board Members

Greg Licholai MD
Richard Mott
Andrew ElBardissi MD
Deerfield Management
Kevin Wasserstein
Neurotechnology Innovations Translator
Gregory Fiore MD
Steven Hochberg

Other companies like Sollis Therapeutics in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
 
 
Sector
Last Round Est. Valuation
$317.32MM
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$1.59B
Sector
Last Round Est. Valuation
$4.26B
Sector